
Pharmacally
ANKTIVA
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in ANKTIVA
Health TidingsImmunityBio Reports QUILT-2.005 Success for ANKTIVA Plus BCGImmunityBio announced that ANKTIVA plus BCG met the primary endpoint in the randomized QUILT-2.005 trial in BCG-naïve high-grade non-muscle invasive bladder cancer.Fact-Checked
Clinical TrialsANKTIVA Plus BCG Delivers Lasting Responses, with 84.2% Cystectomy-Free Survival at Three YearsLong-term findings from the QUILT-3.032 study show a 71% complete response rate with ANKTIVA plus BCG in BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ.Fact-Checked
New Drug ApprovalFDA Expands ANKTIVA Approval to High-Grade Papillary-Only Bladder CancerANKTIVA plus BCG for BCG-unresponsive high-grade papillary bladder cancer following expanded FDA approval…Fact-Checked
New Drug ApprovalUAE Approves ANKTIVA for Bladder Cancer and Advanced Lung CancerThe UAE has approved ANKTIVA (nogapendekin alfa inbakicept) for adults with BCG-unresponsive non-muscle invasive bladder cancer and metastatic non-small cell lung cancer after checkpoint inhibitor failure.Fact-Checked
Health TidingsANKTIVA Plus BCG Shows Economic Edge in NMIBC CISPreliminary ISPOR 2026 findings suggest ANKTIVA® plus BCG may reduce healthcare costs while sustaining bladder‑preserving outcomes in BCG‑unresponsive NMIBC CIS.Fact-Checked
Health TidingsImmunityBio’s ANKTIVA sBLA for Papillary NMIBC Accepted by FDAImmunityBio announced FDA acceptance of its supplemental Biologics License Application (sBLA) for ANKTIVA in combination with BCG in patients with BCG‑unresponsive papillary non‑muscle invasive bladder cancer (NMIBC) without…Fact-Checked
Health TidingsImmunityBio Expands ANKTIVA Patent Protection in NMIBC Through 2035ImmunityBio received five U.S. patents covering ANKTIVA + BCG combinations in non-muscle invasive bladder cancer, protecting treatment regimens, commercial kits, and clinical applications as the company advances Phase…Fact-Checked
Health TidingsImmunityBio Launches ANKTIVA in Saudi Arabia for Bladder and Lung CancerImmunityBio, Inc. has introduced ANKTIVA in Saudi Arabia for bladder and lung cancer indications, expanding immunotherapy access in the region after regulatory clearance by the Saudi Food and…Fact-Checked
Health TidingsImmunityBio Says ANKTIVA TV Ad Never Aired, Removes PodcastImmunityBio said it addressed FDA OPDP concerns tied to ANKTIVA promotional content, removed a podcast, and confirmed the referenced television advertisement was never broadcast.Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.